Following strong growth in 2020 due to COVID-19 and consumers stockpiling adult acetaminophen, in particular, analgesics is projected to see a small decline in overall value sales in Norway in 2021. The decline will be a result of a decline in COVID-19 infection cases and a successful vaccination roll-out in the country.
Adult diclofenac is expected to see a significant sales decline in 2021, compared to the mild decline forecast for other types of analgesics. The reason for this is because, from November 2021, diclofenac tablets will switch to prescription only.
Enforced quarantines, restrictions on travel, and work-from-home policies resulted in consumers opting for purchases through e-commerce rather than store-based retailers in 2020. This led to strong growth of analgesics products in e-commerce in 2020.
As Norwegian consumers’ lives return to normal over the forecast period with increased levels of outdoor and physical activity as well as the usual strains of modern life, including growing computer use, it is expected that demand for analgesics will continue to grow. Following a small correction in 2021, solid value sales growth is expected over the forecast period, giving further opportunities for new and existing players.
As consumers increasingly focus on a more holistic and natural approach to their health and wellbeing, it is likely that some consumers will also turn to alternative pain management solutions such as natural and home remedies, massage, sauna, light therapy etc. This may lead to a slightly reduced demand for analgesics over the forecast period, limiting sales growth rates.
Analgesics in Norway continues to be relatively stagnant and largely dominated by a few major players. Karo Pharma AS is likely to maintain its dominant position due to offering the top brand in adult acetaminophen, Paracet, and in adult ibuprofen, Ibux.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Understand the latest market trends and future growth opportunities for the Analgesics industry in Norway with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in Norway, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).See All of Our Definitions
This report originates from Passport, our Analgesics research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!